Invalid Antiretroviral Combination (Multiple NRTIs)

This entry represents a list of multiple antiretroviral medications, specifically nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), with duplications, rather than a single approved combination drug. The list includes abacavir, emtricitabine, tenofovir disoproxil, lamivudine, zidovudine, stavudine, and zalcitabine. This specific combination is **not** a standard or recommended therapy for HIV. In clinical practice, these medications are typically used in specific dual or triple NRTI combinations (e.g., Abacavir/Lamivudine, Tenofovir Disoproxil Fumarate/Emtricitabine, Zidovudine/Lamivudine) often combined with other classes of antiretrovirals. Using all or many of these NRTIs together, especially those with overlapping resistance profiles or toxicities (like stavudine, zidovudine, and zalcitabine which have significant historical toxicities), is not supported by clinical evidence, can lead to increased drug interactions, heightened toxicity without additive benefit, and potentially promote the development of drug resistance. Some non-standard combinations containing multiple NRTIs, like TDF+ABC+3TC, have been shown to have high failure rates. Standard HIV treatment guidelines recommend specific, well-tested combinations based on efficacy, safety, and resistance profiles.

Other names

abacavir + emtricitabine + emtricitabine + tenofovir disoproxil + lamivudine + lamivudine + zidovudine + stavudine + tenofovir disoproxil + zalcitabine + zidovudine